Current Controversies In The Surgical Management Of Pancreatic Cancer
Ammar A. Javed, Kanza Aziz, Christopher L. Wolfgang
Published 2016 · Medicine
Download PDFAnalyze on Scholarcy
Pancreatic ductal adenocarcinoma is one of the deadliest malignancies with an extremely poor survival rate. Both environmental and hereditary factors play a role in the development of disease, and early diagnosis is difficult due to early systemic involvement of disease. Thus, a majority of patients are not surgical candidates at the time of diagnosis.
This paper references
The promise and pitfalls of positron emission tomography and single-photon emission computed tomography molecular imaging-guided radiation therapy.
R. Wahl (2011)
Changes in membrane structure induced by electroporation as revealed by rapid-freezing electron microscopy.
D. Chang (1990)
Genetic mutations associated with cigarette smoking in pancreatic cancer.
A. Blackford (2009)
Occupational exposures and pancreatic cancer: a meta-analysis
I. A. Ojajärvi (2000)
Pancreatic cancer and depression: myth and truth
M. Mayr (2010)
Value of laparoscopy in the staging of pancreatic cancer.
D. Camacho (2005)
Life-style risk factors for pancreatic cancer in Louisiana: a case-control study.
R. Falk (1988)
Reported family aggregation of pancreatic cancer within a population-based case-control study in the francophone community in Montreal, Canada
P. Ghadirian (1991)
Carcinoma of the Pancreatic Head and Periampullary Region Tumor Staging with Laparoscopy and Laparoscopic Ultrasonography
T. John (1995)
Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma
M. Wagner (2004)
Genetic susceptibility in pancreatic ductal adenocarcinoma
R. Lochan (2008)
Pancreaticoduodenectomy with vascular resection: margin status and survival duration
J. Tseng (2007)
Neoadjuvant Chemotherapy Generates a Significant Tumor Response in Resectable Pancreatic Cancer Without Increasing Morbidity: Results of a Prospective Phase II Trial
Stefan Heinrich (2008)
Carcinoma of the Pancreas
Jeffrey Adam Drebin (2008)
Utility of Staging Laparoscopy in Subsets of Peripancreatic and Biliary Malignancies
C. Vollmer (2002)
Long-term Results of Partial Pancreaticoduodenectomy for Ductal Adenocarcinoma of the Pancreatic Head: 25-Year Experience
A. Richter (2003)
PET/CT Fusion Scan Enhances CT Staging in Patients with Pancreatic Neoplasms
J. Farma (2008)
Cancer statistics, 2013
R. Siegel (2013)
Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines.
M. Tempero (2012)
Cigarette smoking and pancreatic cancer: an analysis from the International Pancreatic Cancer Case-Control Consortium (Panc4).
C. Bosetti (2012)
Diagnostic evaluation and staging of pancreatic ductal adenocarcinoma.
Caitlin A McIntyre (2015)
Evaluating the Impact of a Single-Day Multidisciplinary Clinic on the Management of Pancreatic Cancer
T. Pawlik (2008)
Cryosurgery for pancreatic cancer.
Kecheng Xu (2013)
Probability of pancreatic cancer following diabetes: a population-based study.
S. Chari (2005)
The value of minimal access surgery in the staging of patients with potentially resectable peripancreatic malignancy.
K. Conlon (1996)
Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies
R. Huxley (2005)
Laparoscopic Staging and Surgical Treatment of Pancreatic Cancer
Thiruvengadam Muniraj (2013)
Imaging of pancreatic adenocarcinoma: update on staging/resectability.
E. Tamm (2012)
Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head.
G. Varadhachary (2008)
Cancer treatment and survivorship statistics, 2012
R. Siegel (2012)
Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial.
J. Neoptolemos (2010)
Feasibility and safety of radiofrequency ablation for locally advanced pancreatic cancer
R. Girelli (2010)
18Fluorodeoxyglucose PET is prognostic of progression-free and overall survival in locally advanced pancreas cancer treated with stereotactic radiotherapy.
D. Schellenberg (2010)
Cancer statistics, 2014
R. Siegel (2014)
Staging laparoscopy with laparoscopic ultrasonography: optimizing resectability in hepatobiliary and pancreatic malignancy.
M. Callery (1997)
Diagnosis and management of pancreatic cancer.
M. S. D. de la Cruz (2014)
Phase I study of oxaliplatin, full-dose gemcitabine, and concurrent radiation therapy in pancreatic cancer.
S. Desai (2007)
Pancreatic carcinoma: differences between patients with or without diabetes mellitus.
C. Girelli (1995)
Defined Clinical Classifications Are Associated with Outcome of Patients with Anatomically Resectable Pancreatic Adenocarcinoma Treated with Neoadjuvant Therapy
Ching-Wei D. Tzeng (2011)
Microwave ablation of pancreatic head cancer: safety and efficacy.
G. Carrafiello (2013)
Prospective phase II trial of neoadjuvant chemotherapy with gemcitabine and cisplatin for resectable adenocarcinoma of the pancreatic head.
S. Heinrich (2008)
Epidemiology of Pancreatic Cancer: An Update
P. Maisonneuve (2010)
Pretreatment Assessment of Resectable and Borderline Resectable Pancreatic Cancer: Expert Consensus Statement
M. Callery (2009)
Vascular invasion in pancreatic cancer: Imaging modalities, preoperative diagnosis and surgical management.
N. Buchs (2010)
Longer Course of Induction Chemotherapy Followed by Chemoradiation Favors Better Survival Outcomes for Patients With Locally Advanced Pancreatic Cancer
F. Faisal (2016)
Neoadjuvant chemoradiation therapy with gemcitabine/cisplatin and surgery versus immediate surgery in resectable pancreatic cancer
Henriette M B Golcher (2014)
Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head.
D. Evans (2008)
Diagnostic laparoscopy for periampullary and pancreatic cancer: What is the true benefit?
C. Barreiro (2002)
Current utility of staging laparoscopy for pancreatic and peripancreatic neoplasms.
R. White (2008)
Recent progress in pancreatic cancer
C. Wolfgang (2013)
Histopathological Response to Preoperative Chemoradiation for Resectable Pancreatic Adenocarcinoma: The French Phase II FFCD 9704-SFRO Trial
R. Le Scodan (2008)
Does the Use of Neoadjuvant Therapy for Pancreatic Adenocarcinoma Increase Postoperative Morbidity and Mortality Rates?
A. Cooper (2014)
Anthropometric measures, body mass index, and pancreatic cancer: a pooled analysis from the Pancreatic Cancer Cohort Consortium (PanScan).
A. Arslan (2010)
Pancreatic cancer. Assessment of prognosis by clinical presentation
M. Kalser (1985)
Tumour cryoablation combined with palliative bypass surgery in the treatment of unresectable pancreatic cancer: a retrospective study of 142 patients
Jingdong Li (2010)
Adjuvant chemoradiation for pancreatic cancer: few good data, much debate.
Renée Twombly (2008)
Radiofrequency ablation combined with palliative surgery may prolong survival of patients with advanced cancer of the pancreas
J. Spiliotis (2006)
Preoperative/Neoadjuvant Therapy in Pancreatic Cancer: A Systematic Review and Meta-analysis of Response and Resection Percentages
S. Gillen (2010)
Microsecond and nanosecond electric pulses in cancer treatments.
M. Breton (2012)
Family history of cancer and risk of pancreatic cancer: A pooled analysis from the Pancreatic Cancer Cohort Consortium (PanScan)
E. Jacobs (2010)
Surgery for pancreatic cancer: recent controversies and current practice.
C. Wray (2005)
Importance of Age of Onset in Pancreatic Cancer Kindreds
K. Brune (2010)
Cryosurgery with combination of 125iodine seed implantation for the treatment of locally advanced pancreatic cancer
Ke Xu (2008)
Familial pancreatic cancer in south Louisiana.
T. F. Price (1996)
Survival following pancreaticoduodenectomy with resection of the superior mesenteric–portal vein confluence for adenocarcinoma of the pancreatic head
S. Leach (1998)
Therapy of locally unresectable pancreatic carcinoma: A randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5‐fluorouracil), and high dose radiation + 5‐fluorouracil. The gastrointestinal tumor study group
C. Moertel (1981)